Science

Strides gets USFDA nod for Ibuprofen OTC oral suspension

Our Bureau Bengaluru | Updated on February 24, 2021

Strides is focusing on building a private label business in the US by leveraging its portfolio of products across soft gels, tablets, capsules, topicals, powders and oral solutions

Strides Pharma Science Limited has announced that its step-down wholly-owned subsidiary, Strides Pharma Global Pte Limited, Singapore, has received approval for Ibuprofen Oral Suspension USP, 100 mg/5 mL (OTC) from the United States Food & Drug Administration (USFDA).

Ibuprofen OTC Oral Suspension Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) used to relieve pain from various conditions such as headache, dental pain, and muscle aches. It is also used to reduce fever and to relieve minor aches and pains due to the common cold or flu. The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Children’s Motrin Oral Suspension, 100 mg/mL, of Johnson & Johnson Consumer Inc.

Strides is focusing on building a private label business in the US by leveraging its portfolio of products across soft gels, tablets, capsules, topicals, powders and oral solutions. Ibuprofen Oral Suspension USP,100 mg/5 mL (OTC) further strengthens the company’s private label portfolio for the US market.

According to IRi data, the US market for Ibuprofen Oral Suspension USP, 100 mg/5 mL (OTC) is about $133 million. The product will be manufactured at the company’s facility at Bengaluru.

The company has 127 cumulative ANDA filings with USFDA of which 99 ANDAs have been approved and 28 are pending approval.

Published on February 24, 2021

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor